TKNO Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 16:54):

Stats
Šios dienos apimtis	8 282.00
Vidutinė apimtis	12 920.00
Rinkos kapitalizacija	69.52M
EPS	$0 ( 2024-03-11 )
Kita pelno data	( $0 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.470
ATR14	$0.0330 (1.94%)

Insider Trading

Date	Person	Action	Amount	type
2022-08-16	Grossman Paul David	Buy	4 386	Common Stock
2022-08-15	Grossman Paul David	Buy	4 826	Common Stock
2023-08-31	Mcnamara Robert	Sell	12 292	Non-Qualified Stock Option (right to buy)
2023-06-02	Mcnamara Robert	Buy	18 815	Common Stock
2023-08-31	Mcnamara Robert	Sell	18 815	Common Stock

INSIDER POWER
97.74
Last 82 transactions
Buy: 28 174 863 \| Sell: 2 326 861

Alpha Teknova, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
AGNCM	0.863
BRKH	0.861
DOOO	0.859
CMTL	0.859
BTAI	0.841
FLL	0.835
CVCY	0.834
CLGN	0.828
EUSG	0.825
EUFN	0.815

10 Labiausiai neigiamai susiję koreliacijos
CMLF	-0.809

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Alpha Teknova, Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$36.68M
Bruto pelnas:	$9.15M (24.94 %)
EPS:	$-1.160

FY	2023
Pajamos:	$36.68M
Bruto pelnas:	$9.15M (24.94 %)
EPS:	$-1.160

FY	2022
Pajamos:	$41.42M
Bruto pelnas:	$17.48M (42.19 %)
EPS:	$-1.690

FY	2021
Pajamos:	$36.89M
Bruto pelnas:	$17.62M (47.76 %)
EPS:	$-0.464

Financial Reports:

No articles found.

Alpha Teknova, Inc.

Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.